Neurologic clinical trials - Namenda TAME

Status:

In Process (Study opening soon)

ClinicalTrials.gov:

NCT02118727

The purpose of this study is to determine if memantine at 20 mg BID when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS.

Drug

Drug: Memantine, placebo

Trial Type

Interventional

Age Range

18 years or older

Condition

Amyotrophic Lateral Sclerosis (ALS)

Keywords

Amyotrophic Lateral Sclerosis (ALS) | Frontal Temporal Dementia | memantine | riluzole